Open AccessComparative safe-reduction of body weight in rats by using different doses of formalin
Author(s) -
Sarah Saad Abdul Ameer,
Rawaa Hamid Abdulshahed
Publication year - 2022
Publication title -
international journal of health sciences (ijhs) (en línea)
Language(s) - English
Resource type - Journals
eISSN - 2550-6978
pISSN - 2550-696X
DOI - 10.53730/ijhs.v6ns1.4911
Subject(s) - body weight , creatinine , medicine , statistical significance , weight loss , obesity , pharmacology
Body weight gain and obesity have a significant influence on quality of life since they are related with comorbidities and psychological issues. The latter is far more significant than most people think. Formoline L112, a formulation containing polyglucosamine, a chitosan derivative, is one of the most often used products in Europe to help people lose weight. Aim of the study: to evaluate dose-related body weight reduction in rats with possible measuring of drug's safety. Materials and method: 30 rat were classified into 3 groups; group 1 (No.=10) used as control, group 2 (No.=10) given 1 tablet of formoline, and group 3 (No.=10) was given 2 tablet each 12 hours\day. The body weight of each rat was taken before and 30 days after treatment. Blood urea and serum creatinine was assessed before and after using the drug to exclude renal injury. Results: there was significant reduction (at P<0.05) in body weight by using either single or double doses of formoline as compared to control group with no statistical significance of using single dose as compared to double dose.